Maurice Petitou
Research Subjects
Research Interests
Maurice Petitou has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Jean-Marc Herbert
2 shared publicationsPhilippe Duchaussoy
2 shared publicationsPhilippe Sizun
Sanofi-Synthélabo Recherche, DARA, 371, rue du Professeur-Joseph-Blayac, 34184 Montpellier cedex, France
2 shared publicationsAnne Imberty
CERMAV‐CNRS (affiliated with Université Joseph Fourier) P 53, F38041 Grenoble cedex 9 (France)
1 shared publicationEric Garrigou
1 shared publication- Eugen Sisu
Department of Biochemistry and Pharmacology, “Victor Babes” University of Medicine and Pharmacy, RO-300041 Timisoara, Romania
1 shared publication
Latest Publications
- 23 September 2002
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 28 (4) , 393-402
The Synthetic Pentasaccharide Fondaparinux: First in the Class of Antithrombotic Agents that Selectively Inhibit Coagulation Factor Xa
Fondaparinux (Arixtra®), a synthetic pentasaccharide, is the first in a new class of antithrombotic agents that selectively inhibit coagulation factor Xa. In vitro experiments demonstrated that it is a selective inhibitor of factor Xa. In plasma, fondaparinux selectively binds to antithrombin, catalyzes factor Xa inhibition, and thereby inhibits thrombin generation. Its antithrombotic efficacy has been demonstrated in various animal models mimicking venous and arterial thrombosis. In humans, its pharmacokinetic profile is favorable, with a rapid onset of antithrombotic activity and an elimination half-life allowing a convenient once-daily dosing regimen. In several clinical trials, fondaparinux was more effective than the reference drug, enoxaparin, in preventing venous thromboembolism after hip fracture, major knee, and elective hip replacement surgeries. The overall reduction in the risk of venous thromboembolism ranged between 26.3 and 56.4%, depending on the trial. This superior efficacy was achieved without increasing the risk of clinically relevant bleeding. Fondaparinux also showed promising results in the treatment of patients with venous thromboembolism and acute coronary syndromes. Thus, it is now established that selective factor Xa inhibition is an efficient way to prevent venous thrombosis. The advent of fondaparinux offers an opportunity to improve substantially the management of venous thromboembolism.
- 23 September 2002
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 28 (4) , 393-402
The Synthetic Pentasaccharide Fondaparinux: First in the Class of Antithrombotic Agents that Selectively Inhibit Coagulation Factor Xa
Fondaparinux (Arixtra®), a synthetic pentasaccharide, is the first in a new class of antithrombotic agents that selectively inhibit coagulation factor Xa. In vitro experiments demonstrated that it is a selective inhibitor of factor Xa. In plasma, fondaparinux selectively binds to antithrombin, catalyzes factor Xa inhibition, and thereby inhibits thrombin generation. Its antithrombotic efficacy has been demonstrated in various animal models mimicking venous and arterial thrombosis. In humans, its pharmacokinetic profile is favorable, with a rapid onset of antithrombotic activity and an elimination half-life allowing a convenient once-daily dosing regimen. In several clinical trials, fondaparinux was more effective than the reference drug, enoxaparin, in preventing venous thromboembolism after hip fracture, major knee, and elective hip replacement surgeries. The overall reduction in the risk of venous thromboembolism ranged between 26.3 and 56.4%, depending on the trial. This superior efficacy was achieved without increasing the risk of clinically relevant bleeding. Fondaparinux also showed promising results in the treatment of patients with venous thromboembolism and acute coronary syndromes. Thus, it is now established that selective factor Xa inhibition is an efficient way to prevent venous thrombosis. The advent of fondaparinux offers an opportunity to improve substantially the management of venous thromboembolism.
- 16 February 2001
- Published by Wiley in Chemistry – A European Journal
- Vol. 7 (4) , 858-873
Experimental Proof for the Structure of a Thrombin-Inhibiting Heparin Molecule
- 16 February 2001
- Published by Wiley in Chemistry – A European Journal
- Vol. 7 (4) , 858-873
Experimental Proof for the Structure of a Thrombin-Inhibiting Heparin Molecule